ÚLTIMAS PUBLICACIONES (2018-2026)

Gottesdiener LS, Li Y, Greenwood-Quaintance KE, Komarow L, Arias CA, Cober E, Herc ES, Kaye KS, Huskins WC, Figueroa J, Vilchez S, Fries BC, Leroi M, McCarty TP, Rioseco ML, Munita JM, Stryjewski ME, Reyes J, Chen L, Kreiswirth BN, Hill C, Baum K, Villegas MV, Paterson DL, Bonomo RA, Chambers HF, Fowler VG Jr, Patel R, Doi Y, van Duin D and Satlin MJ.
Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant Pseudomonas aeruginosa and clinical implications in the prospective observational Pseudomonas study (2026).
DOI: https://doi.org/10.1128/aac.00388-25
Antimicrobial Agents and Chemotherapy:e0038825

Lamb G, Pallett SJC, Charani E, Kanu EM, Alqahtani SA, Villegas MV and Moore LSP.
Assessment of the Prioritization of Diagnostics in National Action Plans for Antimicrobial Resistance (2026).
DOI: https://doi.org/10.1093/cid/ciag020
Clinical Infectious Diseases:ciag020

Rojas LJ, De La Cadena E, Marshall SH, Rudin SD, García P, Serrano NC, Meneses LS, Villegas MV and Bonomo RA.
Enterobacter hormaechei co-harbouring blaKPC-2, blaVIM-24, and blaNDM-1: the rise of the ‘unholy trinity’ (2026).
DOI: https://doi.org/10.1093/jacamr/dlag025
JAC-Antimicrobial Resistance 8(1):dlag025

Espitia-Acero C, García-Betancur JC, De La Cadena E, Pallares CJ, Restrepo-Arbeláez N, Patiño-Guevara E, Coy M and Villegas MV.
Colonization status and risk factors for infection by carbapenem-resistant Gram-negative bacteria in intensive care units in Colombia (2026).
DOI: https://doi.org/10.1016/j.jhin.2025.11.003
Journal of Hospital Infection 168:183-190

Restrepo-Arbeláez N, Lemos-Luengas EV, García-Betancur JC, Cornistein W, Boldim-Ferreira D, Ahumada R, Chaverri-Murillo J, Castañeda-Méndez P, Hercilla L and Villegas MV.
Cost-Analysis of Adherence to Antimicrobial Guidelines as Part of Antimicrobial Stewardship Strategies in 6 Latin American Countries: A Pilot Experience Focusing on Economic Impact (2026).
DOI: https://doi.org/10.1016/j.vhri.2025.101550
Value in Health Regional Issues 51:101550

Cadena E, Esparza G, García-Betancur JC, Restrepo-Arbeláez N, Castro BE, Pallares CJ and Villegas MV.
High in vitro activity of Fosfomycin in carbapenemase-producing Klebsiella pneumoniae and carbapenem-resistant Pseudomonas aeruginosa in clinical isolates in Colombia (2026).
DOI: https://doi.org/10.1016/j.diagmicrobio.2025.117110
Diagnostic Microbiology and Infectious Disease 114(1):117110

Horcajada JP, Gales AC, Isler B, Kaye KS, Kwa A, Landersdorfer CB, Montero MM, Oliver A, Pogue JM, Shields RK, Villegas MV, Yahav D and Paterson DL.
Current and future options for the treatment of serious infections due to carbapenem-resistant Pseudomonas aeruginosa (2025).
DOI: https://doi.org/10.1128/cmr.00233-24
Clinical Microbiology Reviews 38(4):e0023324

Castro BE, De la Cadena E, Escobar-Arcos JJ, García-Betancur JC, Restrepo-Arbeláez N, Pallares C, López MJ, Pescador A, Escobar TJ, Matta-Cortes L, Palacios-Larrota AC and Villegas MV.
Emergence and dissemination of blaKPC-31 and blaPAC-2 among different species of Enterobacterales in Colombia: a new challenge for the microbiological laboratories (2025).
DOI: https://doi.org/10.1128/spectrum.01805-25
Microbiology Spectrum 13(11):e0180525

García-Betancur JC, Pallares CJ, Restrepo-Arbeláez N, De La Cadena E, Cornistein W, Byró PS, Boldim-Ferreira D, Ahumada R, Valdebenito N, Chaverri-Murillo J, Castañeda-Méndez P, Toledo I, Vente EY, Hercilla L, Moreno V, Goff DA and Villegas MV.
Antimicrobial stewardship interventions reduce the time to the first antibiotic administration in septic patients in ICUs: regional multicenter study in 7 Latin American high-complexity hospitals (2025).
DOI: https://doi.org/10.1128/aac.01850-24
Antimicrobial Agents and Chemotherapy 69(8):e0185024

Goff DA, Amir A, Ashiru-Oredope D, Balasa E, Carter V, Dramowski A, Flayhart D, Kanj S, Rossi F, Schellack N, Shader Smith D, Thursky K, van den Bergh D and Villegas MV.
Women trailblazers shaping the global future of antimicrobial stewardship and antimicrobial resistance (2025).
DOI: https://doi.org/10.1080/14787210.2025.2530623
Expert Review of Anti-infective Therapy 1-7

Augustyniak M, García-Betancur JC, Péloquin S, Esparza G, Pallares CJ, Rosselli D, De Luna D, Lazure P and Villegas MV.
Promoting real-world evidence use for antimicrobial stewardship in Latin America: evaluation of impact of a two-part educational webinar series (2025).
DOI: https://doi.org/10.1093/jacamr/dlaf056
JAC-Antimicrobial Resistance 7(2):dlaf056

Motta F, Nizamuddin S, Khan E, Muraya T, Vega S, Fadare J, Koya SF, Villegas MV, Sultan F, Lumley T, Dwivedi R, Jankelowitz L and Cohn J.
A Landscaping Assessment and Call-to-Action to Improve Access to Novel Reserve Antibiotics in 14 Low- and Middle-Income Countries (2024).
DOI: https://doi.org/10.1002/puh2.70005
Public Health Challenges 3(4):e70005

Restrepo-Arbeláez N, García-Betancur JC, Pallares CJ, El Ayoubi LW, Kiratisin P, Kanj SS and Villegas MV.
Can risk factors and risk scores help predict colonization and infection in multidrug-resistant gram-negative bacteria? (2024).
DOI: https://doi.org/10.1017/ash.2024.455
Antimicrobial Stewardship & Healthcare Epidemiology 4(1):e196

De la Cadena E, Mojica MF, Rojas LJ, Castro BE, García-Betancur JC, Marshall SH, Restrepo N, Castro-Caro NP, Fonseca-Carrillo M, Pallares C, Bonomo RA and Villegas MV.
First report of KPC variants conferring ceftazidime-avibactam resistance in Colombia: introducing KPC-197 (2024).
DOI: https://doi.org/10.1128/spectrum.04105-23
Microbiology Spectrum 12(6):e0410523

De La Cadena E, Pallares CJ, García-Betancur JC, Porras JA and Villegas MV.
Actualización sobre la resistencia antimicrobiana en instituciones de salud de nivel III y IV en Colombia entre enero del 2018 y diciembre del 2021 (2023).
DOI: https://doi.org/10.7705/biomedica.7065
Biomedica 43(4):457-473

Restrepo-Arbeláez N, Garcia-Betancur JC, Pallares CJ and Villegas MV.
Antimicrobial Stewardship Programs in Latin America and the Caribbean: A Story of Perseverance, Challenges, and Goals (2023).
DOI: https://doi.org/10.3390/antibiotics12081342
Antibiotics 12(8):1342

Lazure P, Augustyniak M, Goff DA, Villegas MV, Apisarnthanarak A and Peloquin S.
Gaps and barriers in the implementation and functioning of antimicrobial stewardship programmes: results from an educational and behavioural mixed-methods needs assessment in France, the United States, Mexico and India-authors’ response (2023).
DOI: https://doi.org/10.1093/jacamr/dlad082
JAC-Antimicrobial Resistance 5(4):dlad082

Pallares CJ, Porras J, De La Cadena E, García-Betancur JC, Restrepo-Arbeláez N, Viveros SMC, Cornistein W, Castañeda-Méndez P, Cuellar L, Boldim-Ferreira D, Chaverri-Murillo J, Labarca JA and Villegas MV.
Antimicrobial stewardship programs in seven Latin American countries: facing the challenges (2023).
DOI: https://doi.org/10.1186/s12879-023-08398-3
BMC Infectious Diseases 23(1):463

Moore LSP, Villegas MV, Wenzler E, Rawson TM, Oladele RO, Doi Y and Apisarnthanarak A.
Rapid Diagnostic Test Value and Implementation in Antimicrobial Stewardship Across Low-to-Middle and High-Income Countries: A Mixed-Methods Review (2023).
DOI: https://doi.org/10.1007/s40121-023-00815-z
Infectious Diseases and Therapy 12(6):1445-1463

Mojica MF, De La Cadena E, García-Betancur JC, Porras J, Novoa-Caicedo I, Páez-Zamora L, Pallares C, Appel TM, Radice MA, Castañeda-Méndez P, Gales AC, Munita JM and Villegas MV.
Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals (2023).
DOI: https://doi.org/10.1128/msphere.00651-22
mSphere 8(2):e0065122

De La Cadena E, Mahecha M, Velandia AM, García-Betancur JC, Rojas LJ, Porras J, Pallares C and Villegas MV.
Identification of mcr-1 Genes and Characterization of Resistance Mechanisms to Colistin in Escherichia coli Isolates from Colombian Hospitals (2023).
DOI: https://doi.org/10.3390/antibiotics12030488
Antibiotics 12(3):488

Reyes J, Komarow L, Chen L, Ge L, Hanson BM, Cober E, Herc E, Alenazi T, Kaye KS, Garcia-Diaz J, Li L, Kanj SS, Liu Z, Oñate JM, Salata RA, Marimuthu K, Gao H, Zong Z, Valderrama-Beltrán SL, Yu Y, Tambyah P, Weston G, Salcedo S, Abbo LM, Xie Q, Ordoñez K, Wang M, Stryjewski ME, Munita JM, Paterson DL, Evans S, Hill C, Baum K, Bonomo RA, Kreiswirth BN, Villegas MV, Patel R, Arias CA, Chambers HF, Fowler VG Jr, Doi Y, van Duin D and Satlin MJ.
Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study (2023).
DOI: https://doi.org/10.1016/S2666-5247(22)00329-9
Lancet Microbe 4(3):e159-e170

Mojica MF, De La Cadena E, Ríos R, García-Betancur JC, Díaz L, Reyes J, Hernández-Gómez C, Radice M, Gales AC, Castañeda Méndez P, Munita JM, Pallares CJ, Martínez JRW and Villegas MV.
Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries (2022).
DOI: https://doi.org/10.3389/fmicb.2022.1035609
Frontiers in Microbiology 13:1035609

Lazure P, Augustyniak M, Goff DA, Villegas MV, Apisarnthanarak A and Péloquin S.
Gaps and barriers in the implementation and functioning of antimicrobial stewardship programmes: results from an educational and behavioural mixed methods needs assessment in France, the United States, Mexico and India (2022).
DOI: https://doi.org/10.1093/jacamr/dlac094
JAC-Antimicrobial Resistance 4(5):dlac094

Bassetti M, Kanj SS, Kiratisin P, Rodrigues C, Van Duin D, Villegas MV and Yu Y.
Early appropriate diagnostics and treatment of MDR Gram-negative infections (2022).
DOI: https://doi.org/10.1093/jacamr/dlac089
JAC-Antimicrobial Resistance 4(5):dlac089

Kanj SS, Bassetti M, Kiratisin P, Rodrigues C, Villegas MV, Yu Y and van Duin D.
Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections (2022).
DOI: https://doi.org/10.1016/j.ijantimicag.2022.106633
International Journal of Antimicrobial Agents 60(3):106633

García-Betancur JC, De La Cadena E, Mojica MF, Hernández-Gómez C, Correa A, Radice MA, Castañeda-Méndez P, Jaime-Villalon DA, Gales AC, Munita JM and Villegas MV.
Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries (2022).
DOI: https://doi.org/10.3390/antibiotics11081101
Antibiotics 11(8):1101

Goff DA, Gauthier TP, Langford BJ, Prusakov P, Ubaka Chukwuemka M, Nwomeh BC, Yunis KA, Saad T, van den Bergh D, Villegas MV, Martinez N, Morris A, Ashiru-Oredope D, Howard P and Sanchez PJ.
Global resilience and new strategies needed for antimicrobial stewardship during the COVID-19 pandemic and beyond (2022).
DOI: https://doi.org/10.1002/jac5.1622
Journal of the American College of Clinical Pharmacy 5(7):707-715

Pallares C, Hernández-Gómez C, Appel TM, Escandón K, Reyes S, Salcedo S, Matta L, Martínez E, Cobo S, Mora L, Marín A, Correa A, De La Cadena E, Rodríguez-Baño J and Villegas MV.
Impact of antimicrobial stewardship programs on antibiotic consumption and antimicrobial resistance in four Colombian healthcare institutions (2022).
DOI: https://doi.org/10.1186/s12879-022-07410-6
BMC Infectious Diseases 22(1):420

Wang M, Earley M, Chen L, Hanson BM, Yu Y, Liu Z, Salcedo S, Cober E, Li L, Kanj SS, Gao H, Munita JM, Ordoñez K, Weston G, Satlin MJ, Valderrama-Beltrán SL, Marimuthu K, Stryjewski ME, Komarow L, Luterbach C, Marshall SH, Rudin SD, Manca C, Paterson DL, Reyes J, Villegas MV, Evans S, Hill C, Arias R, Baum K, Fries BC, Doi Y, Patel R, Kreiswirth BN, Bonomo RA, Chambers HF, Fowler VG Jr, Arias CA and van Duin D.
Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study (2022).
DOI: https://doi.org/10.1016/S1473-3099(21)00399-6
Lancet Infectious Diseases 22(3):401-412

Gill CM, Aktaş E, Alfouzan W, Bourassa L, Brink A, Burnham CD, Canton R, Carmeli Y, Falcone M, Kiffer C, Marchese A, Martinez O, Pournaras S, Satlin MJ, Seifert H, Thabit AK, Thomson KS, Villegas MV and Nicolau DP.
Multicenter, Prospective Validation of a Phenotypic Algorithm to Guide Carbapenemase Testing in Carbapenem-Resistant Pseudomonas aeruginosa Using the ERACE-PA Global Surveillance Program (2021).
DOI: https://doi.org/10.1093/ofid/ofab617
Open Forum Infectious Diseases 9(2):ofab617

Gill CM, Aktaş E, Alfouzan W, Bourassa L, Brink A, Burnham CD, Canton R, Carmeli Y, Falcone M, Kiffer C, Marchese A, Martinez O, Pournaras S, Satlin M, Seifert H, Thabit AK, Thomson KS, Villegas MV, Nicolau DP and ERACE-PA Global Study Group.
The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa (2021).
DOI: https://doi.org/10.1007/s10096-021-04308-0
European Journal of Clinical Microbiology & Infectious Diseases 40(12):2533-2541

Gill CM, Aktaş E, Alfouzan W, Bourassa L, Brink A, Burnham CD, Canton R, Carmeli Y, Falcone M, Kiffer C, Marchese A, Martinez O, Pournaras S, Seifert H, Thabit AK, Villegas MV, Westblade LF, Nicolau DP and ERACE-PA Global Study Group.
Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization (2021).
DOI: https://doi.org/10.1128/AAC.01204-21
Antimicrobial Agents and Chemotherapy 65(11):e0120421

Rada AM, De La Cadena E, Agudelo CA, Pallares C, Restrepo E, Correa A, Villegas MV and Capataz C.
Genetic Diversity of Multidrug-Resistant Pseudomonas aeruginosa Isolates Carrying blaVIM-2 and blaKPC-2 Genes That Spread on Different Genetic Environment in Colombia (2021).
DOI: https://doi.org/10.3389/fmicb.2021.663020
Frontiers in Microbiology 12:663020

Appel TM, Quijano-Martínez N, De La Cadena E, Mojica MF and Villegas MV.
Microbiological and Clinical Aspects of Raoultella spp. (2021).
DOI: https://doi.org/10.3389/fpubh.2021.686789
Frontiers in Public Health 9:686789

Villegas MV, Esparza G and Reyes J.
Should ceftriaxone-resistant Enterobacterales be tested for ESBLs? A PRO/CON debate (2021).
DOI: https://doi.org/10.1093/jacamr/dlab035
JAC-Antimicrobial Resistance 3(2):dlab035

De La Cadena E, Mojica MF, García-Betancur JC, Appel TM, Porras J, Pallares CJ, Solano-Gutiérrez JS, Rojas LJ and Villegas MV.
Molecular Analysis of Polymyxin Resistance among Carbapenemase-Producing Klebsiella pneumoniae in Colombia (2021).
DOI: https://doi.org/10.3390/antibiotics10030284
Antibiotics 10(3):284

Maraolo AE, Corcione S, Grossi A, Signori A, Alicino C, Hussein K, Trecarichi EM, Viale P, Timsit JF, Veeraraghavan B, Villegas MV, Rahav G, Daikos GL, Vardakas KZ, Roilides E, Uhlemann AC, Ghafur AK, Mornese Pinna S, Bassetti M, Kohler PP and Giacobbe DR.
The Impact of Carbapenem Resistance on Mortality in Patients With Klebsiella Pneumoniae Bloodstream Infection: An Individual Patient Data Meta-Analysis of 1952 Patients (2021).
DOI: https://doi.org/10.1007/s40121-021-00408-8
Infectious Diseases and Therapy 10(1):541-558

García-Betancur JC, Appel TM, Esparza G, Gales AC, Levy-Hara G, Cornistein W, Vega S, Nuñez D, Cuellar L, Bavestrello L, Castañeda-Méndez PF, Villalobos-Vindas JM and Villegas MV.
Update on the epidemiology of carbapenemases in Latin America and the Caribbean (2021).
DOI: https://doi.org/10.1080/14787210.2020.1813023
Expert Review of Anti-infective Therapy 19(2):197-213

De La Cadena E, Mojica MF, Castillo N, Correa A, Appel TM, García-Betancur JC, Pallares CJ and Villegas MV.
Genomic Analysis of CTX-M-Group-1-Producing Extraintestinal Pathogenic E. coli (ExPEc) from Patients with Urinary Tract Infections (UTI) from Colombia (2020).
DOI: https://doi.org/10.3390/antibiotics9120899
Antibiotics 9(12):899

Rada AM, De La Cadena E, Agudelo C, Capataz C, Orozco N, Pallares C, Dinh AQ, Panesso D, Ríos R, Diaz L, Correa A, Hanson BM, Villegas MV, Arias CA and Restrepo E.
Dynamics of blaKPC-2 Dissemination from Non-CG258 Klebsiella pneumoniae to Other Enterobacterales via IncN Plasmids in an Area of High Endemicity (2020).
DOI: https://doi.org/10.1128/AAC.01743-20
Antimicrobial Agents and Chemotherapy 64(12):e01743-20

Mojica MF, De La Cadena E, Hernández-Gómez C, Correa A, Appel TM, Pallares CJ and Villegas MV.
Performance of disk diffusion and broth microdilution for fosfomycin susceptibility testing of multidrug-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa (2020).
DOI: https://doi.org/10.1016/j.jgar.2020.01.003
Journal of Global Antimicrobial Resistance 21:391-395

Mojica MF, De La Cadena E, Correa A, Appel TM, Pallares CJ and Villegas MV.
Evaluation of Allplex™ Entero-DR assay for detection of antimicrobial resistance determinants from bacterial cultures (2020).
DOI: https://doi.org/10.1186/s13104-020-04997-4
BMC Research Notes 13(1):154

Appel TM, Mojica MF, De La Cadena E, Pallares CJ, Radice MA, Castañeda-Méndez P, Jaime-Villalón DA, Gales AC, Munita JM and Villegas MV.
In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries (2020).
DOI: https://doi.org/10.3390/antibiotics9020062
Antibiotics 9(2):62

Gutiérrez S, Correa A, Hernández-Gómez C, De La Cadena E, Pallares C and Villegas MV.
Detection of carbapenemase-producing Pseudomonas aeruginosa: Evaluation of the carbapenem inactivation method (CIM) (2019).
DOI: https://doi.org/10.1016/j.eimc.2019.02.004
Enfermedades Infecciosas y Microbiología Clínica 37(10):648-651

Hernández-Gómez C, Hercilla L, Mendo F, Pérez-Lazo G, Contreras E, Ramírez E, Flores W, Julca Á, Chuquiray N, Arenas B, Abarca S, Viñas M, Linares E, Villegas MV and Illescas LR.
Programas de optimización del uso de antimicrobianos en Perú: Un acuerdo sobre lo fundamental (2019).
DOI: https://doi.org/10.4067/S0716-10182019000500565
Revista Chilena de Infectología 36(5):565-575

Ordóñez K, Feinstein MM, Reyes S, Hernández-Gómez C, Pallares C and Villegas MV.
Clinical and economic impact of generic versus brand name meropenem use in an intensive care unit in Colombia (2019).
DOI: https://doi.org/10.1016/j.bjid.2019.06.010
Brazilian Journal of Infectious Diseases 23(4):237-245

Rada AM, Hernández-Gómez C, Restrepo E and Villegas MV.
Distribution and molecular characterization of beta-lactamases in Gram-negative bacteria in Colombia, 2001-2016 (2019).
DOI: https://doi.org/10.7705/biomedica.v39i3.4351
Biomedica 39(s1):199-220

Villegas MV and Lyon S.
Gram-negative infections: evolving treatments with expanding options (2018).
DOI: https://doi.org/10.4155/fsoa-2018-0071
Future Science OA 4(9):FSO339

De La Cadena E, Correa A, Muñoz JS, Rojas LJ, Hernández-Gómez C, Pallares C, Perez F, Bonomo RA and Villegas MV.
Molecular characterisation of carbapenem-resistant Enterobacter cloacae complex in Colombia: blaKPC and the ‘changing landscape’ (2018).
DOI: https://doi.org/10.1016/j.jgar.2017.12.008
Journal of Global Antimicrobial Resistance 13:184-189